{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:20:33Z","timestamp":1782796833589,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS081366"],"award-info":[{"award-number":["R01NS081366"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS121038"],"award-info":[{"award-number":["R01NS121038"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002108","name":"Friedreich's Ataxia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"US Office of Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["HT9425-23-1-0337"],"award-info":[{"award-number":["HT9425-23-1-0337"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtn.2025.102617","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:42:40Z","timestamp":1751427760000},"page":"102617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antisense oligonucleotide therapy for patients with Friedreich\u2019s ataxia carrying the c.165+5G>C splicing mutation"],"prefix":"10.1016","volume":"36","author":[{"given":"Pouir\u00e9","family":"Yameogo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thazha P.","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill S.","family":"Napierala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-0641","authenticated-orcid":false,"given":"Marek","family":"Napierala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102617_bib1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102617_bib2","first-page":"197","article-title":"Friedreich ataxia: Detection of GAA repeat expansions and frataxin point mutations","volume":"126","author":"Pandolfo","year":"2006","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.omtn.2025.102617_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","article-title":"Friedreich's ataxia: pathology, pathogenesis, and molecular genetics","volume":"303","author":"Koeppen","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.omtn.2025.102617_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng0897-345","article-title":"Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin","volume":"16","author":"Koutnikova","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102617_bib5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nature08301","article-title":"Function and biogenesis of iron-sulphur proteins","volume":"460","author":"Lill","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102617_bib6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ana.24595","article-title":"Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia","volume":"79","author":"Galea","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2025.102617_bib7","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/acn3.52027","article-title":"Phenotypic variation of FXN compound heterozygotes in a Friedreich ataxia cohort","volume":"11","author":"Shen","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omtn.2025.102617_bib8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1261\/rna.070987.119","article-title":"Exon size and sequence conservation improves identification of splice-altering nucleotides","volume":"25","author":"Movassat","year":"2019","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2025.102617_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrm3525","article-title":"Alternative splicing: a pivotal step between eukaryotic transcription and translation","volume":"14","author":"Kornblihtt","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102617_bib10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1261\/rna.876308","article-title":"Splicing regulation: from a parts list of regulatory elements to an integrated splicing code","volume":"14","author":"Wang","year":"2008","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2025.102617_bib11","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/nsmb.2377","article-title":"Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules","volume":"19","author":"Wang","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.omtn.2025.102617_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad014","article-title":"Discovering cryptic splice mutations in cancers via a deep neural network framework","volume":"5","author":"Teboul","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.omtn.2025.102617_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41586-020-1970-0","article-title":"Genomic basis for RNA alterations in cancer","volume":"578","author":"PCAWG Transcriptome Core Group","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102617_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9062004","article-title":"Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omtn.2025.102617_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40259-024-00644-7","article-title":"Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases","volume":"38","author":"Chen","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.omtn.2025.102617_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1304342","article-title":"Antisense oligonucleotides: a novel Frontier in pharmacological strategy","volume":"14","author":"Collotta","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102617_bib17","doi-asserted-by":"crossref","DOI":"10.52965\/001c.24934","article-title":"The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy","volume":"13","author":"Edinoff","year":"2021","journal-title":"Orthop. Rev."},{"key":"10.1016\/j.omtn.2025.102617_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/nat.2021.0067","article-title":"Modulation of RNA Splicing by Oligonucleotides: Mechanisms of Action and Therapeutic Implications","volume":"32","author":"Sergeeva","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2025.102617_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/JND-221648","article-title":"The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience","volume":"10","author":"Aartsma-Rus","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2025.102617_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.31662\/jmaj.2021-0019","article-title":"Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy","volume":"4","author":"Matsuo","year":"2021","journal-title":"JMA J"},{"key":"10.1016\/j.omtn.2025.102617_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102617_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2021.0039","article-title":"Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives","volume":"32","author":"Synofzik","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2025.102617_bib23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s13311-019-00764-x","article-title":"Molecular Mechanisms and Therapeutics for the GAA.TTC Expansion Disease Friedreich Ataxia","volume":"16","author":"Gottesfeld","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.omtn.2025.102617_bib24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1089\/bio.2015.0117","article-title":"Establishment and Maintenance of Primary Fibroblast Repositories for Rare Diseases-Friedreich's Ataxia Example","volume":"14","author":"Li","year":"2016","journal-title":"Biopreserv. Biobank."},{"key":"10.1016\/j.omtn.2025.102617_bib25","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s12276-024-01292-1","article-title":"Tailored antisense oligonucleotides designed to correct aberrant splicing reveal actionable groups of mutations for rare genetic disorders","volume":"56","author":"Wai","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omtn.2025.102617_bib26","doi-asserted-by":"crossref","first-page":"11560","DOI":"10.1093\/nar\/gkab954","article-title":"Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression","volume":"49","author":"Li","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102617_bib27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1089\/hum.2020.053","article-title":"Defining Transcription Regulatory Elements in the Human Frataxin Gene: Implications for Gene Therapy","volume":"31","author":"Li","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102617_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/nat.2013.0463","article-title":"Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology","volume":"24","author":"Juliano","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2025.102617_bib29","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1126\/science.aan6414","article-title":"Synthetic transcription elongation factors license transcription across repressive chromatin","volume":"358","author":"Erwin","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102617_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.tibs.2012.02.002","article-title":"Design principles of interconnections between chromatin and pre-mRNA splicing","volume":"37","author":"de Almeida","year":"2012","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.omtn.2025.102617_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26082263","article-title":"RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays","volume":"26","author":"Tang","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2025.102617_bib32","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.omtn.2020.07.036","article-title":"Antisense Oligonucleotide- and CRISPR-Cas9-Mediated Rescue of mRNA Splicing for a Deep Intronic CLRN1 Mutation","volume":"21","author":"Panagiotopoulos","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102617_bib33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3389\/fnins.2018.00589","article-title":"New Antibody-Free Mass Spectrometry-Based Quantification Reveals That C9ORF72 Long Protein Isoform Is Reduced in the Frontal Cortex of Hexanucleotide-Repeat Expansion Carriers","volume":"12","author":"Viode","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omtn.2025.102617_bib34","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.1093\/nar\/gky395","article-title":"Blocking of an intronic splicing silencer completely rescues IKBKAP exon 20 splicing in familial dysautonomia patient cells","volume":"46","author":"Bruun","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102617_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/humu.22931","article-title":"Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides","volume":"37","author":"Igreja","year":"2016","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2025.102617_bib36","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102617_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cells12192395","article-title":"Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide. Cells 12","volume":"12","author":"Haque","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102617_bib38","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102617_bib39","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102617_bib40","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2025.102617_bib41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102617_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105218","article-title":"Exosome-mediated delivery of antisense oligonucleotides targeting alpha-synuclein ameliorates the pathology in a mouse model of Parkinson's disease","volume":"148","author":"Yang","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtn.2025.102617_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.65","article-title":"Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain","volume":"2","author":"Rungta","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102617_bib44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/17425247.5.1.105","article-title":"Cell-penetrating peptides for drug delivery across membrane barriers","volume":"5","author":"Foged","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.omtn.2025.102617_bib45","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.addr.2016.06.008","article-title":"Peptides for nucleic acid delivery","volume":"106","author":"Lehto","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102617_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/biom9010022","article-title":"Combination of Cell-Penetrating Peptides with Nanoparticles for Therapeutic Application: A Review","volume":"9","author":"Silva","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.omtn.2025.102617_bib47","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102617_bib48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.omtn.2025.102617_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10048-019-00594-1","article-title":"The first biallelic missense mutation in the FXN gene in a consanguineous Turkish family with Charcot-Marie-Tooth-like phenotype","volume":"21","author":"Candayan","year":"2020","journal-title":"Neurogenetics"},{"key":"10.1016\/j.omtn.2025.102617_bib50","unstructured":"Friedreich's Ataxia Research Alliance (2024). LX2006 Gene Therapy. https:\/\/www.curefa.org\/drug-development\/lx2006-gene-therapy\/."},{"key":"10.1016\/j.omtn.2025.102617_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.836476","article-title":"Selected Histone Deacetylase Inhibitors Reverse the Frataxin Transcriptional Defect in a Novel Friedreich's Ataxia Induced Pluripotent Stem Cell-Derived Neuronal Reporter System","volume":"16","author":"Schreiber","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omtn.2025.102617_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189990","article-title":"Somatic instability of the expanded GAA repeats in Friedreich's ataxia","volume":"12","author":"Long","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102617_bib53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:35:08Z","timestamp":1777322108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125001714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2162253125001714"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102617","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense oligonucleotide therapy for patients with Friedreich\u2019s ataxia carrying the c.165+5G>C splicing mutation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102617"}}